Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3,7-Epoxycaryophyllan-6-Ol SCHEMBL24176356 | 0.73 | CYP3A4 (1.00) | CYP3A4ALDH1A1 | |
| 3,7-Epoxycaryophyllan-6-Ol SCHEMBL24176170 | 0.73 | CYP3A4 (1.00) | CYP3A4ALDH1A1 | |
| SCHEMBL4192842 | 0.69 | CYP3A4 (0.54) | CYP3A4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4272327 | 0.68 | CYP3A4 (0.41) | CYP3A4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL22417663 | 0.67 | CYP3A4 (0.57) | CYP3A4ALDH1A1LMNAMAPTRECQL | |
| SCHEMBL29801778 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1LMNAMAPTUSP2 | |
| SCHEMBL24176299 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1LMNAMAPTUSP2 | |
| SCHEMBL15944367 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1LMNAMAPTUSP2 | |
| SCHEMBL9832207 | 0.62 | CYP3A4 (0.46) | CYP3A4LMNAMAPTTSHRMAPK1 | |
| SCHEMBL13625216 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | CYP3A4 2876/4885ALDH1A1 860/4885LMNA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.